NYSE$UHS
Universal Health Services Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
UHS's financial performance was marked by increased revenues, offset by a slight decrease in net income and adjusted EBITDA compared to the same quarter last year.
Universal Health Services, Inc. reported a net income attributable to UHS of $167.0 million, or $2.40 per diluted share, for Q3 2023, compared to $182.8 million, or $2.50 per diluted share, for Q3 2022. Net revenues increased by 6.8% to $3.563 billion. Adjusted net income attributable to UHS was $177.5 million, or $2.55 per diluted share, compared to $185.8 million, or $2.54 per diluted share, for the same period last year.
- Net revenues increased by 6.8% to $3.563 billion.
- Net income attributable to UHS was $167.0 million, or $2.40 per diluted share.
- Adjusted net income attributable to UHS was $177.5 million, or $2.55 per diluted share.
- The company repurchased 1.32 million shares at an aggregate cost of approximately $175.1 million.
Headline financials
Revenue & EPS history
UHS · Revenue · Quarterly
$3.56B
Revenue by segment
UHS · $3.56B total across 2 segments · Q3 2023
- Acute Care Services$2.02B+5.1%56.7%
- Behavioral Health Services$1.54B+7.5%43.3%
Forward guidance
This press release contains forward-looking statements based on current management expectations. Numerous factors may cause the results to differ materially from those anticipated in the forward-looking statements. These statements are subject to risks and uncertainties and therefore actual results may differ materially.
Tailwinds
- Gaining or building high quality hospitals in rapidly growing markets.
- Investing in the people and equipment needed to allow each facility to thrive.
- Becoming the leading healthcare provider in each community we serve.
Headwinds
- Nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue.
- The impact of the COVID-19 pandemic has had a material effect on our operations and financial results.
- A significant portion of our revenues are derived from federal and state government programs including the Medicare and Medicaid programs.
- The increase in interest rates has substantially increased our borrowings costs and reduced our ability to access the capital markets on favorable terms.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+0.7%
Avg return
30 days after
49%
34 / 69 earnings
Positive
+17.5%
Q3 2022
Best reaction
-13.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.5% | -7.0% | -16.4% | |
| Q4 2025 | -5.5% | -1.0% | -9.9% | |
| Q3 2025 | +2.5% | +1.4% | +14.1% | |
| Q2 2025 | -0.2% | +3.3% | +7.3% | |
| Q1 2025 | -0.6% | +3.4% | +10.5% | |
| Q4 2024 | +3.3% | -3.8% | +3.4% | |
| Q3 2024 | -13.4% | -12.1% | -15.5% | |
| Q2 2024 | +10.6% | +17.3% | +25.8% | |
| Q1 2024 | +0.1% | +2.6% | +6.9% | |
| Q4 2023 | -1.6% | +4.1% | +11.0% | |
| Q3 2023 | -0.2% | -0.6% | +11.4% | |
| Q2 2023 | -4.6% | -6.5% | -12.3% | |
| Q1 2023 | +1.5% | +6.9% | -9.3% | |
| Q4 2022 | -9.1% | -13.5% | -15.5% | |
| Q3 2022 | +17.5% | +25.8% | +39.3% | |
| Q2 2022 | -1.5% | +1.3% | -5.7% | |
| Q1 2022 | -5.7% | -7.8% | -8.1% | |
| Q4 2021 | +8.6% | +8.7% | +11.1% | |
| Q3 2021 | -7.0% | -8.5% | -5.0% | |
| Q2 2021 | +4.2% | +5.1% | +1.6% | |
| Q1 2021 | +0.3% | +2.0% | +10.1% | |
| Q4 2020 | -9.1% | -6.2% | -2.0% | |
| Q3 2020 | +3.0% | +11.1% | +24.2% | |
| Q2 2020 | +0.9% | +1.7% | +0.2% | |
| Q1 2020 | +3.7% | -2.5% | +8.6% | |
| Q4 2019 | -5.3% | -2.7% | -34.3% | |
| Q3 2019 | -4.6% | -4.0% | -3.6% | |
| Q2 2019 | +10.9% | +11.6% | +4.7% | |
| Q1 2019 | -0.8% | -2.6% | -5.5% | |
| Q4 2018 | +3.9% | +2.7% | +0.1% | |
| Q3 2018 | -5.3% | -1.0% | +8.0% | |
| Q2 2018 | +9.3% | +9.3% | +12.0% | |
| Q1 2018 | -4.6% | -5.2% | -3.2% | |
| Q4 2017 | -1.3% | +5.3% | +0.7% | |
| Q3 2017 | -6.9% | -8.3% | -9.9% | |
| Q2 2017 | -9.2% | -10.3% | -12.6% | |
| Q1 2017 | -2.0% | -0.1% | -3.0% | |
| Q4 2016 | -0.9% | -0.8% | -0.8% | |
| Q3 2016 | +0.6% | -0.7% | +1.3% | |
| Q2 2016 | -4.4% | -5.2% | -12.1% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | +2.1% | — | — | |
| Q1 2015 | -0.7% | — | — | |
| Q4 2014 | +3.8% | — | — | |
| Q3 2014 | -1.0% | — | — | |
| Q2 2014 | +6.8% | — | — | |
| Q1 2014 | +8.3% | — | — | |
| Q4 2013 | -2.6% | — | — | |
| Q3 2013 | +2.6% | — | — | |
| Q2 2013 | +3.3% | — | — | |
| Q1 2013 | +3.3% | — | — | |
| Q4 2012 | -0.0% | — | — | |
| Q3 2012 | -3.2% | — | — | |
| Q2 2012 | +4.8% | — | — | |
| Q1 2012 | -1.7% | — | — | |
| Q2 2011 | +2.0% | — | — | |
| Q4 2011 | +2.0% | — | — | |
| Q3 2011 | +3.8% | — | — | |
| Q1 2010 | +3.8% | — | — | |
| Q4 2010 | +3.8% | — | — | |
| Q1 2011 | +3.8% | — | — | |
| Q2 2010 | +5.0% | — | — | |
| Q3 2009 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q4 2009 | -0.3% | — | — | |
| Q2 2009 | -0.3% | — | — | |
| Q4 2008 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro